Navigation Links
9-PCV vaccine found to be helpful in invasive Pneumonococcal infection

Randomized double blind placebo controlled trial was done by Felicity cutts and colleagues in Gambia on the efficacy of // a Nine Valent Pneumococcal Conjugate Vaccine (9-PCV) against radiologically confirmed pneumonia and invasive pneumococcal disesase in children immunized before 12 months of age.

The vaccine was found to reduce the incidence of vaccine type invasive pneumococcal disease by 77%, all serotype invasive Pneumococcal disease by 50%, all the hospital admissions by 15% and overall child mortality by 16%.

The 9-PCV trial reports the higher reduction in the incidence of radiological pneumonia than California and South African studies. The 9-PCV vaccines are used to help the fourth UN Millennium Development Goal in reducing the childhood mortality in developing countries. The evidence for efficacy of the vaccine in all hospital admissions is high.

Chest radiograph has shown high efficacy of the 9-PCV vaccines against pneumonia. The vaccine can also be used as an epidemiological tool to determine the amount of pneumonia due to Pneumococcus. Vaccine efficacy is detected by comparing the percentage reduction of disease incidence in a vaccinated group compared with an unvaccinated group.

In this study the scientists used WHO pneumonia case management algorithm for identifying clinical pneumonia and also WHO radiology standardized guidelines for reading chest radiographs. , Placebo, vaccine trial, nine valent pneumococcal conjugate vaccine, 9PCV, infection, pneumonia, disease, children, serotype, trial report, chest radiograph, WHO.
'"/>




Page: 1

Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... its newly designed TaskMate Go. Core benefits and advantages built into the home ... a stylish, functional look and feel. Ability to gain the benefits embedded in ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the ... Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run of ... book measures almost a metre across when open, weighs in at more than six ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
Breaking Medicine Technology: